Bank of America Raises Integer (NYSE:ITGR) Price Target to $145.00

Integer (NYSE:ITGRFree Report) had its target price upped by Bank of America from $135.00 to $145.00 in a report issued on Tuesday morning, Benzinga reports. Bank of America currently has a buy rating on the medical equipment provider’s stock.

Several other brokerages have also recently issued reports on ITGR. Benchmark restated a buy rating and issued a $130.00 target price on shares of Integer in a report on Friday, August 2nd. Truist Financial raised their target price on shares of Integer from $137.00 to $145.00 and gave the stock a buy rating in a report on Tuesday. Finally, Oppenheimer initiated coverage on shares of Integer in a report on Tuesday, July 16th. They issued an outperform rating and a $135.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $137.29.

Read Our Latest Analysis on Integer

Integer Trading Up 2.6 %

ITGR stock opened at $129.11 on Tuesday. The company has a market capitalization of $4.33 billion, a PE ratio of 44.67, a price-to-earnings-growth ratio of 1.87 and a beta of 1.08. Integer has a one year low of $69.40 and a one year high of $131.87. The company’s 50 day moving average price is $123.88 and its two-hundred day moving average price is $119.52. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.96 and a current ratio of 3.29.

Integer (NYSE:ITGRGet Free Report) last posted its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 EPS for the quarter, topping the consensus estimate of $1.24 by $0.06. The firm had revenue of $436.20 million for the quarter, compared to the consensus estimate of $437.00 million. Integer had a net margin of 6.31% and a return on equity of 11.48%. The business’s revenue was up 9.0% compared to the same quarter last year. During the same period last year, the firm posted $1.14 earnings per share. As a group, analysts predict that Integer will post 5.31 earnings per share for the current fiscal year.

Insider Activity at Integer

In other Integer news, Director Jean M. Hobby sold 11,960 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the completion of the transaction, the director now owns 2,280 shares of the company’s stock, valued at approximately $272,824.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 2.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Integer

Several institutional investors and hedge funds have recently added to or reduced their stakes in ITGR. Quest Partners LLC raised its position in shares of Integer by 3,688.9% in the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 332 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Integer by 60.9% in the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 142 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Integer in the 1st quarter worth about $106,000. Innealta Capital LLC purchased a new position in shares of Integer in the 2nd quarter worth about $110,000. Finally, Hancock Whitney Corp purchased a new position in Integer in the 1st quarter worth about $203,000. Hedge funds and other institutional investors own 99.29% of the company’s stock.

About Integer

(Get Free Report)

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.

Recommended Stories

Analyst Recommendations for Integer (NYSE:ITGR)

Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.